The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE‐1407)

LESSONS LEARNED: Palbociclib demonstrated no detectable activity in molecularly unselected and heavily pretreated patients with advanced grade 1/2 pancreatic neuroendocrine tumors. Predictive biomarkers that improve patient selection should be investigated in future studies of palbociclib. BACKGROUN...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Grande, Enrique, Teulé, Alex, Alonso‐Gordoa, Teresa, Jiménez‐Fonseca, Paula, Benavent, Marta, Capdevila, Jaume, Custodio, Ana, Vera, Ruth, Munarriz, Javier, La Casta, Adelaida, Díez, Juan José, Gajate, Pablo, Molina‐Cerrillo, Javier, Matos, Ignacio, Cristóbal, Eva María, Ruffinelli, José C., Palacios, José, García‐Carbonero, Rocío
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485337/
https://ncbi.nlm.nih.gov/pubmed/32045050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0033
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars